GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...
2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...
Medpage Today on MSN7d
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
The Optical PSMA Imaging Agent (IR-800 IAB2 Minibody) is a fluorescent labelled minibody that binds the PSMA receptor present on cancer cells including prostate cancer and is used for quantitative, ...
is a fluorescent labelled minibody that binds the PSMA receptor present on cancer cells including prostate cancer and is used for quantitative, non-invasive PET imaging of PSMA+ cells in ...
Sydney-based Clarity Pharmaceuticals has received a third fast track designation (FTD) from the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback